BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sturlimogene erparepvec readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sturlimogene erparepvec\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06623110-10918@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Sturlimogene erparepvec: Phase 2 readout est. (NCT06623110)
DESCRIPTION:Sturlimogene erparepvec\, phase 2.\nStudy: Phase II Study of RP
 2 as Immunoprevention in High-Risk Oral Precancerous Disease\nEstimated pr
 imary completion: 1 January 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/sturlimogene-erparepvec#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06623110
URL:https://assetmemo.bio/drug/sturlimogene-erparepvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059611-10918@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Sturlimogene erparepvec: Phase 2 readout est. (NCT07059611)
DESCRIPTION:Sturlimogene erparepvec\, phase 2.\nStudy: Neoadjuvant Intra-tu
 moral RP2 and FLOT in Gastroesophageal Adenocarcinoma\nEstimated primary c
 ompletion: 1 November 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/sturlimogene-erparepvec#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07059611
URL:https://assetmemo.bio/drug/sturlimogene-erparepvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05733598-10918@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Sturlimogene erparepvec: Phase 2 readout est. (NCT05733598)
DESCRIPTION:Sturlimogene erparepvec\, phase 2.\nStudy: Study of RP2 in Comb
 ination With Second-line Therapy in Patients With Locally Advanced or Meta
 static HCC\nEstimated primary completion: 1 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/sturlimogene-erparepvec#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05733598
URL:https://assetmemo.bio/drug/sturlimogene-erparepvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07862530-10918@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20280227
DTEND;VALUE=DATE:20280228
SUMMARY:Sturlimogene erparepvec: Phase 2 readout est. (NCT07862530)
DESCRIPTION:Sturlimogene erparepvec\, phase 2.\nStudy: Neoadjuvant RP2 + Ni
 volumab in Patients With Melanoma\nEstimated primary completion: 27 Februa
 ry 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/sturlimogene
 -erparepvec#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07862530
URL:https://assetmemo.bio/drug/sturlimogene-erparepvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06581406-10918@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Sturlimogene erparepvec: Phase 2/3 readout est. (NCT06581406)
DESCRIPTION:Sturlimogene erparepvec\, phase 2/3\, Uveal Melanoma.\nStudy: A
  Randomized\, Phase 2/3 Study to Investigate the Efficacy and Safety of RP
 2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adul
 t Patients With Metastatic Uveal Melanoma\nEstimated primary completion: J
 anuary 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sturlimo
 gene-erparepvec#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06581406
URL:https://assetmemo.bio/drug/sturlimogene-erparepvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
